FDA Approves Clinical Trials for South Korean COVID-19 Drug Candidate

Clinical trials of the cancer drug GX-17, in the experimental phase for the treatment of COVID-19 patients, have been authorized by the Food and Drug Administration (FDA).

Jointly developed by the US-based biopharmaceutical company NeoImmuneTech Inc, GX-17 will be administered to adult COVID-19 patients with moderate symptoms, the company said.

GX-17 is an immunotherapy drug that targets interleukin-7, whose role is essential in the proliferation of T cells in the body.

Genexine is a member of a consortium of six companies, including SK Life Science Inc., a subsidiary of the country’s third-largest conglomerate SK, to develop new COVID-19 vaccines.
The consortium has successfully tested its vaccine on monkeys. Binex, a member of the consortium, has completed the production of a sample.